While large-scale biobanks often lack pediatric data, AMIGO (Advanced Medical Intelligence for Guiding Omics-based Medicine) is transforming the landscape by connecting (gen)omics and clinical longitudinal data from Europe’s leading children’s hospitals. This secure ecosystem makes fragmented clinical and genetic information accessible for pharmaceutical research without compromising patient privacy.
Why This Matters
Children with rare diseases frequently lack approved treatments because traditional pediatric clinical trials are often too small and prohibitively expensive. AMIGO solves this by:
-
Lowering Costs: Bringing together data across diseases and hospitals to reduce the effort required for pharma to test treatments.
-
Scaling Innovation: Allowing advanced bioinformatics and AI algorithms to scale from biotech labs to the patient’s bedside.
-
Building Ecosystems: Connecting “AI-first” pharma companies with the real-world data, advanced algorithms, and CROs necessary for regulatory alignment.
Opportunities for Pharma Partners
Through the IHI Call 12 funding initiative, pharmaceutical partners can gain access to real-world pediatric data across Europe to:
-
Repurpose Drugs: Find new indications for existing medications.
-
Validate Biomarkers: Discover and validate biomarkers using real-world evidence.
-
Enhance Trials: Use in-silico modeling and trial simulation to improve study design.
-
Advance AI: Develop and train machine learning models via federated learning.
Interested in joining the mission? You can contribute internal staff time to secure exclusive access across Europe for specific disease areas.
Contact the Project Leads:
Daniel Weiss (Technical Project Lead): daniel.weiss@med.uni-muenchen.de | +49 89 4400 57451
Nicola Götzenberger (Managing Project Lead): nicola.goetzenberger@med.uni-muenchen.de
Download Flyer here
